Bluestar Managing Director Erin Olsen is back from the ASCO conference in Chicago and joins Principal Jeff Fineberg on the podcast again, this time to talk about all things antibody drug conjugates (ADCs) in oncology.

Given the number and value of deals in this space over the past couple of years, as well as the 170+ ADCs now in clinical development, Jeff asks Erin to take stock of what we’ve learned about the potential of these molecules, with all of their moving parts, and opine on what lies ahead.

Over the course of this brief conversation, Erin and Jeff touch on some key questions about ADCs, including:

• Are ADCs living up to their promise?
• What are some lessons learned from Enhertu?
• What have we learned about TOP1 payloads and TROP2 targeting?
• Have ADCs delivered on better safety than chemo?
• What’s next for ADCs?